Inclusion Criteria:

- Primary and secondary MDS, AML after MDS, and de novo AML relapsing after
allogeneic stem cell transplantation

- Eligibility for Donor Lymphocyte Infusions

- Performance status according to the WHO scale: 0, 1 or 2.

- Adequate renal and liver function: bilirubin < 1.5 times the upper limit
of normal and a GFR > 50 ml/min

- Absence of severe cardiovascular disease, i.e., arrhythmias requiring chronic
treatment, congestive heart failure (NYHA Class III or IV) or symptomatic
ischemic heart disease, where New-York Heart Association (NYHA)

- HIV negative and HBs-Ag negative.

- Absence of active uncontrolled infection (Septicaemia).

- No prior history or current evidence of central nervous system and psychiatric
disorders requiring hospitalization.

- Age at least 18 years.

- Negative pregnancy test for women with reproductive potential.

- Signed written informed consent must be given according to national/local
regulations.

Exclusion Criteria:

- Have malignant hepatic tumors.

- Severe liver dysfunction CHILD B and C.

- Renal insufficiency with a GFR < 50 ml/min

- Radiation therapy, chemotherapy, or cytotoxic therapy, given to treat conditions
other than MDS, AML or applied for conditioning prior allogeneic stemcell
transplantation.

- Psychiatric illness that would prevent granting of informed consent.

- Treatment with androgenic hormones during the previous 14 days prior Day 1.

- Active viral infection with known human immunodeficiency virus (HIV) or viral
Hepatitis B or C.

- Hypersensitivity to Mannitol or 5-Azacitidine.

- Treatment with other investigational drugs following relapse after allogeneic
stemcell transplantation or ongoing adverse events from previous treatment with
investigational drugs regardless of time period.